Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
Cancers · 16.03.2023 · 15 (6) · 1798
DOI: 10.3390/cancers15061798 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.03.2023. Verfasst von Takeshi Hatanaka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 371-0821, Japan. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Transarterial chemoembolization (TACE) has been standard treatment for intermediate-stage hepatocellular carcinoma (HCC). However, all intermediate-stage HCC patients did not benefit from TACE treatment because intermediate-stage HCC encompasses a wide variety of HCCs. Owing to remarkable progress in systemic therapy, including molecular-targeted therapy for advanced-stage HCC, the standard treatment of HCC has recently shifted to systemic therapy. However, it remains controversial as to which treatment should be initially performed for intermediate-stage HCC. In addition, although curative treatment can be considered when the tumor shrinks, the timing of conversion therapy remains uncertain. This review summarizes the advances of HCC treatment and discusses treatment strategies for intermediate-stage HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 371-0821, Japan.
- Department of Gastroenterology, Hanwa Memorial Hospital, Osaka 558-0041, Japan.
- Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan.
- Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan.
ORCID-Profile: Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki
Zitieren
APA
Hatanaka, T., Yata, Y., Naganuma, A., & Kakizaki, S. (2023). Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy. Cancers, 15(6), 1798. https://doi.org/10.3390/cancers15061798
Vancouver
Hatanaka T, Yata Y, Naganuma A, Kakizaki S. Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy. Cancers. 2023;15(6):1798. doi:10.3390/cancers15061798
BibTeX
@article{Hatanaka2023,
author = {Hatanaka, Takeshi and Yata, Yutaka and Naganuma, Atsushi and Kakizaki, Satoru},
title = {Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy},
journal = {Cancers},
year = {2023},
volume = {15},
number = {6},
pages = {1798},
doi = {10.3390/cancers15061798}
}
EUVIMED